Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free RUA Stock Alerts

RUA Life Sciences (RUA) Competitors

RUA Life Sciences logo
GBX 23.16 -0.74 (-3.08%)
As of 11:50 AM Eastern
Compare

RUA vs. IUG, NCYT, IHC, AVO, and SUN

Should you buy RUA Life Sciences stock or one of its competitors? MarketBeat compares RUA Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RUA Life Sciences include Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), and Surgical Innovations Group (SUN). These companies are all part of the "medical devices" industry.

How does RUA Life Sciences compare to Intelligent Ultrasound Group?

RUA Life Sciences (LON:RUA) and Intelligent Ultrasound Group (LON:IUG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Intelligent Ultrasound Group'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
Intelligent Ultrasound Group Neutral

RUA Life Sciences has a net margin of -3.26% compared to Intelligent Ultrasound Group's net margin of -23.11%. RUA Life Sciences' return on equity of -2.03% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

0.1% of RUA Life Sciences shares are held by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are held by institutional investors. 7.3% of RUA Life Sciences shares are held by company insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Intelligent Ultrasound Group has higher revenue and earnings than RUA Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M3.50-£2.66MN/AN/A
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

RUA Life Sciences has a beta of 0.948, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Summary

Intelligent Ultrasound Group beats RUA Life Sciences on 5 of the 9 factors compared between the two stocks.

How does RUA Life Sciences compare to Novacyt?

RUA Life Sciences (LON:RUA) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

RUA Life Sciences has a beta of 0.948, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, suggesting that its stock price is 11% more volatile than the broader market.

RUA Life Sciences has a net margin of -3.26% compared to Novacyt's net margin of -103.08%. RUA Life Sciences' return on equity of -2.03% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Novacyt -103.08%-96.44%-27.98%

In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
Novacyt Neutral

0.1% of RUA Life Sciences shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 7.3% of RUA Life Sciences shares are owned by insiders. Comparatively, 0.4% of Novacyt shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

RUA Life Sciences has higher earnings, but lower revenue than Novacyt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M3.50-£2.66MN/AN/A
Novacyt£20.03M1.50-£36.80M-£32.00N/A

Summary

RUA Life Sciences beats Novacyt on 6 of the 10 factors compared between the two stocks.

How does RUA Life Sciences compare to Inspiration Healthcare Group?

RUA Life Sciences (LON:RUA) and Inspiration Healthcare Group (LON:IHC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Inspiration Healthcare Group had 2 more articles in the media than RUA Life Sciences. MarketBeat recorded 2 mentions for Inspiration Healthcare Group and 0 mentions for RUA Life Sciences. Inspiration Healthcare Group's average media sentiment score of 1.27 beat RUA Life Sciences' score of 0.00 indicating that Inspiration Healthcare Group is being referred to more favorably in the news media.

Company Overall Sentiment
RUA Life Sciences Neutral
Inspiration Healthcare Group Positive

Inspiration Healthcare Group has a net margin of -2.19% compared to RUA Life Sciences' net margin of -3.26%. RUA Life Sciences' return on equity of -2.03% beat Inspiration Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Inspiration Healthcare Group -2.19%-6.49%-3.47%

RUA Life Sciences has a beta of 0.948, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Inspiration Healthcare Group has a beta of 0.872, indicating that its stock price is 13% less volatile than the broader market.

0.1% of RUA Life Sciences shares are held by institutional investors. Comparatively, 7.4% of Inspiration Healthcare Group shares are held by institutional investors. 7.3% of RUA Life Sciences shares are held by insiders. Comparatively, 6.1% of Inspiration Healthcare Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

RUA Life Sciences has higher earnings, but lower revenue than Inspiration Healthcare Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M3.50-£2.66MN/AN/A
Inspiration Healthcare Group£47.55M0.36-£12.20M-£1.16N/A

Summary

RUA Life Sciences and Inspiration Healthcare Group tied by winning 6 of the 12 factors compared between the two stocks.

How does RUA Life Sciences compare to Advanced Oncotherapy?

RUA Life Sciences (LON:RUA) and Advanced Oncotherapy (LON:AVO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Advanced Oncotherapy has a net margin of 0.00% compared to RUA Life Sciences' net margin of -3.26%. RUA Life Sciences' return on equity of -2.03% beat Advanced Oncotherapy's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Advanced Oncotherapy N/A -67.34%-11.73%

In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Advanced Oncotherapy'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
Advanced Oncotherapy Neutral

RUA Life Sciences has higher revenue and earnings than Advanced Oncotherapy.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M3.50-£2.66MN/AN/A
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A

RUA Life Sciences has a beta of 0.948, indicating that its share price is 5% less volatile than the broader market. Comparatively, Advanced Oncotherapy has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market.

0.1% of RUA Life Sciences shares are owned by institutional investors. Comparatively, 17.8% of Advanced Oncotherapy shares are owned by institutional investors. 7.3% of RUA Life Sciences shares are owned by company insiders. Comparatively, 47.5% of Advanced Oncotherapy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

RUA Life Sciences beats Advanced Oncotherapy on 5 of the 9 factors compared between the two stocks.

How does RUA Life Sciences compare to Surgical Innovations Group?

RUA Life Sciences (LON:RUA) and Surgical Innovations Group (LON:SUN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

RUA Life Sciences has a net margin of -3.26% compared to Surgical Innovations Group's net margin of -4.96%. RUA Life Sciences' return on equity of -2.03% beat Surgical Innovations Group's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Surgical Innovations Group -4.96%-6.04%-3.03%

In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Surgical Innovations Group'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
Surgical Innovations Group Neutral

Surgical Innovations Group has higher revenue and earnings than RUA Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M3.50-£2.66MN/AN/A
Surgical Innovations Group£11.60M0.36N/A-£0.10N/A

0.1% of RUA Life Sciences shares are owned by institutional investors. Comparatively, 2.8% of Surgical Innovations Group shares are owned by institutional investors. 7.3% of RUA Life Sciences shares are owned by insiders. Comparatively, 22.2% of Surgical Innovations Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

RUA Life Sciences has a beta of 0.948, meaning that its share price is 5% less volatile than the broader market. Comparatively, Surgical Innovations Group has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Summary

RUA Life Sciences beats Surgical Innovations Group on 5 of the 9 factors compared between the two stocks.

Get RUA Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RUA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RUA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RUA vs. The Competition

Export
MetricRUA Life SciencesMedical Devices IndustryMedical SectorLON Exchange
Market Cap£14.38M£2.15B£6.78B£2.77B
Dividend Yield1.44%2.64%2.67%6.16%
P/E Ratio-2.6115.0727.10368.03
Price / Sales3.50128.99573.9184,416.01
Price / Cash2.4015.9926.6827.89
Price / Book1.084.5510.667.61
Net Income-£2.66M£144.75M£3.60B£5.89B
7 Day Performance-5.45%-0.85%-1.51%-0.06%
1 Month Performance25.56%1.00%1.11%-0.86%
1 Year Performance98.67%-4.88%23.77%61.97%

RUA Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RUA
RUA Life Sciences
N/AGBX 23.17
-3.1%		N/A+105.0%£14.38M£4.11MN/A48
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
NCYT
Novacyt
N/AGBX 36.23
+2.1%		N/A+0.0%£26.25M£20.03MN/A120
IHC
Inspiration Healthcare Group
N/AGBX 18
+2.9%		N/A-15.4%£16.14M£47.55MN/A224
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/AN/A3,900

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:RUA) was last updated on 7/20/2026 by MarketBeat.com Staff.
From Our Partners
Backed Company Could Save Power Grid
A small Colorado company holds the rights to technology that could protect the U.S. public power grid from col...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
NVIDIA offered $40B. The answer was no.
Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...
Behind the Markets | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Trump is positioned. Elon lights the fuse.
Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...
Crypto 101 Media | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel